title: Insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in cystic fibrosis: a positive effect of antibiotic therapy and hyperalimentation.
abstract: Patients with cystic fibrosis (CF) are underweight and growth retarded. This study tested the link between serum insulin-like growth factor-I (IGF-I) and insulin-like growth factor-binding protein-3 (IGFBP-3) levels and body height, nutritional status, pulmonary function tests and activity of inflammation in 92 subjects with CF (age 2.1-18.8 y). It also analysed the effect of short-term antibiotic treatment and hyperalimentation on IGF-I and IGFBP-3 levels in 33 subjects (age 3.6-33.7y) on 41 occasions. Both IGF-I (-1.19 +/- 0.17 SD) and IGFBP-3 levels (-0.66 +/- 0.12 SD; both p < 0.0001 vs 0) were decreased in cross-sectional measurements. Their standardized values were inversely proportional to age (IGF-I: r = -0.23, p = 0.03; IGFBP-3: r = -0.29, p = 0.005) and positively correlated with SDS of height (IGF-I: r = 0.40, p < 0.0001; IGFBP-3: r = 0.36, p = 0.0005) and of mid-arm circumference (IGF-I: r = 0.39, p = 0.0001; IGFBP-3: r = 0.38, p = 0.0002), and with pulmonary function tests. After a short-term course of intensive antibiotic therapy and hyperalimentation, IGF-I normalized (from -0.66 +/- 0.20 to 0.00 +/- 0.25 SD; p < 0.0001) and IGFBP-3 increased (from -0.78 +/- 0.15 to -0.53 +/- 0.16 SD; p = 0.002). IGFBP-3 correlated inversely with erythrocyte sedimentation rate (r = -0.40, p = 0.01).
  
  
  CONCLUSIONS
  The levels of IGF-I and IGFBP-3 are markedly decreased in patients with CF and tend to normalise after a short course of antibiotic treatment and hyperalimentation.
authors.affiliation: Department of Paediatrics, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic. lebl@fnkv.cz
authors.forename: J
authors.initials: J
authors.lastname: Lebl
authors.forename: M
authors.initials: M
authors.lastname: Zahradníková
authors.forename: J
authors.initials: J
authors.lastname: Bartosová
authors.forename: D
authors.initials: D
authors.lastname: Zemková
authors.forename: M
authors.initials: M
authors.lastname: Pechová
authors.forename: V
authors.initials: V
authors.lastname: Vávrová
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents; D001827:Body Height; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D003550:Cystic Fibrosis / Q000097:blood* / Q000178:diet therapy / Q000188:drug therapy; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D006128:Growth; D013007:Growth Hormone-Releasing Hormone / Q000097:blood; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008137:Longitudinal Studies; D008297:Male; D009748:Nutrition Disorders / Q000097:blood / Q000178:diet therapy; D012129:Respiratory Function Tests
chemical_list: D000900:Anti-Bacterial Agents; D018972:Insulin-Like Growth Factor Binding Protein 3; D007334:Insulin-Like Growth Factor I; D013007:Growth Hormone-Releasing Hormone